PMID- 29137408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 48
DP  - 2017 Oct 13
TI  - Incidence and risk of regorafenib-induced hepatotoxicity.
PG  - 84102-84111
LID - 10.18632/oncotarget.21106 [doi]
AB  - Regorafenib, an oral multi-kinase inhibitor, has been approved for the treatments 
      of several malignancies. Unlike traditional cytotoxic chemotherapeutic agents, 
      regorafenib therapy often induces a distinct profile of adverse events (AEs) 
      including hepatotoxicity. Here we conducted an up-to-date meta-analysis to assess 
      the incidence and risk of regorafenib related hepatic toxicities. PubMed and 
      Embase database were reviewed from inception to June 2017 for relevant trials. 
      Eligible studies include subjects with solid tumors treated with 160 mg of 
      regorafenib daily during the first three week of each four-week cycle, and 
      adequate safety data reporting the elevation of aspartate transaminase (AST), 
      alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin. 
      Statistical analyses were conducted to calculate the summary incidence and 
      relative risk (RR). A total of 2,213 subjects from 14 trials were included. The 
      incidences of regorafenib-associated all-grade and high-grade hepatotoxicity 
      were: bilirubin elevation: 23% and 5%; AST elevation: 32% and 6%; ALT elevation: 
      27% and 5%; ALP elevation: 31% and 2%. Regorafenib-treated subjects had a 
      significant increased risk of all-grade (RR = 3.10; 95% CI, 2.22-4.34) and 
      high-grade (RR = 1.74; 95% CI, 1.09-2.80) bilirubin elevation; all-grade (RR = 
      1.51; 95% CI, 1.13-2.00) and high-grade (RR = 1.79; 95% CI, 1.00-3.22) AST 
      elevation; all-grade (RR = 1.82; 95% CI, 1.25-2.64) and high-grade (RR = 3.07; 
      95% CI, 1.30-7.22) ALT elevation; and all-grade (RR = 2.11; 95% CI, 1.01-4.40) 
      ALP elevation. Our results suggest that regorafenib is associated with an 
      increased risk of hepatic toxicities. Hepatotoxicity examination at regular 
      intervals should be advised to clinicians.
FAU - Zhao, Bin
AU  - Zhao B
AD  - The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical 
      University, Wenzhou, 325027, China.
FAU - Zhao, Hong
AU  - Zhao H
AD  - Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical 
      University, Harbin, 150081, China.
LA  - eng
PT  - Journal Article
DEP - 20170920
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
EIN - Oncotarget. 2019 Jan 4;10(2):253. PMID: 30719219
PMC - PMC5663580
OTO - NOTNLM
OT  - adverse event
OT  - cancer
OT  - hepatotoxicity
OT  - regorafenib
COIS- CONFLICTS OF INTEREST None.
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:01
PMCR- 2017/10/13
CRDT- 2017/11/16 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/09/03 00:00 [accepted]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:01 [medline]
PHST- 2017/10/13 00:00 [pmc-release]
AID - 21106 [pii]
AID - 10.18632/oncotarget.21106 [doi]
PST - epublish
SO  - Oncotarget. 2017 Sep 20;8(48):84102-84111. doi: 10.18632/oncotarget.21106. 
      eCollection 2017 Oct 13.